佐思市场研究报告网
最新报告 网站地图 联系我们 登陆 首页
研究报告
报告定制
资料下载
竞争情报
行业情报
企业研究
佐思软件
佐思年鉴
English
报告购买流程
定购方法
① 注册订购:
点击在线订购进行报告订购
我们的服务人员将在24小时内与您联系。

② 电话订购:
拔打电话

北京:010-51266615
    010-82863480/1/2/5
24小时:13436696826
传真:010-82863486

上海:021-64871266
             021-64872612
24小时:13524982235
传真:021-64872324

签订协议
可从网上下载报告订购表或由我们传真报告订购表或订购协议。
传真:010-82863486

付款方式
① 通过银行转帐的形式支付报告购买款项
② 我们收到款项后,24小时内快递报告或者发送报告邮件

③ 款项到帐后快递发票

银行电汇:
北京:
开户行:
上海浦东发展银行北京知春路支行
帐号:91170154740001300
户名: 北京佐思信息咨询有限责任公司
联系人:张小姐

研究报告导航
[TMT产业]
通信业 电子元器件 传媒业
计算机 软件行业 互联网
[医药产业]
化学原料药及化学制剂
中药业 生物制药业
医药综合及医疗器械行业
[化学工业]
化肥和农药 化学纤维 石化
化工综合 日用及有机化工
塑料业
[能源材料]
能源电力 煤炭 有色金属
钢铁 玻璃 新能源新材料
[公共服务]
金融银行 百货零售 旅游 文体娱乐 宏观经济 外贸
[交通运输]
汽车及相关行业 民航业
公路及铁路运输
港口与物流
[日用产品]
家电家居 纺织业
服装业 纸业
[工业设备]
输配电及控制设备
锅炉及原动机 金属制品
专用设备制造 通用设备
[食品其它]
食品饮料 制酒
农林牧渔业 其它
[房产建筑]
房地产 建筑业 水泥
您的位置:佐思研究报告和竞争情报网>>研究报告交易平台>>医药产业>>中药业

亚太地区领先的中医药市场研究报告——Asia Pacific's Leading OTC Medicine Markets
字体
纸介版价格:美元/篇 字数:万字
电子版价格:795美元/篇 页数:
纸介版+电子版价格:美元 图表数:
完成日期:2008-05-30
关键字: 亚太地区|中医药市场|Asia Pacific's |OTC Medicine Markets
 联系方式: 北京:010-51266615 010-82863480/1/2/5 传真:010-82863486  上海:021-64871266 021-64872612 传真:021-64872324    [在线订购]  

摘要:

The Report provides newly researched company profiles and competitive intelligence on over 50 leading OTC producers (see full list below) operating in 14 key markets: Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.

There is great potential in the Asian market for regionally-based OTC manufacturers with strong marketing divisions, but growth rates and trends will be far from uniform across the region. We evaluate and forecast the impact in each state of the key OTC demand drivers; ageing populations, a lower reliance on traditional remedies, the switching of prescription drugs to OTC and increased patient responsibility for healthcare.

Asia Pacific's Leading OTC Medicine Markets features BMI's independent 5-year industry forecasts for each market to end-2012. Crucially, our long term views are founded upon our unique Business Environment Rating – a numerically-based risk-reward evaluation of the competitiveness of the regulatory and business operating environment for each of the 14 OTC markets; a vital tool for benchmarking both the rewards available in each state and the risks of market entry.

Rapid market expansion WILL occur. BMI forecasts that the Asian OTC market will expand at a compound annual growth rate (CAGR) of 7.02% over 2008-2012, with a total market value of US$52bn by 2012 – up from US$36bn in 2007. Moreover, while economic development is a key driver, it is the trends that this propels – a move away from traditional drugs, and government moves to contain healthcare costs – that will determine the rate of OTC market expansion.

'Chindia' will be the key market. Japan is currently the largest OTC market at US$11.02bn in 2007, but growth here will stagnate. The value of its market will be rapidly eclipsed by China and India, which between them will account for 47% of the Asian OTC market by 2012, with analgesics to remain the hottest products.

Furthermore, there are risks. The potential is there, but our forecasts are based on assumptions regarding market access and government health policies that are vulnerable to change. How companies manage these risks will depend on the opportunities available, their ability to build strategic relationships with key stakeholders, and the regional diversification strategies of their clients and competitors.

Key Benefits of the Report

Identify and evaluate the scale of growth opportunities across 14 key markets for OTC producers – including small, growing and little understood markets

Benchmark competitors and peers in each market using recently researched company profiles, featuring latest intelligence on over 50 OTC companies, analysing competitive positioning, opportunities, risks and strategies of each company

Benchmark your own views and forecasts for market performance against BMI's independent 5-year industry forecasts for OTC drugs

Use BMI's country-comparative business environment ratings to assess the operating risks, opportunities and key factors impacting corporate profitability in each of the 14 markets covered

Executives who will benefit most from this Report:

Strategists – Gain an insight into the commercial opportunities available in Asia's OTC market, using our clearly-explained medium-term economic forecasts (2008-2012) to benchmark your own growth projections.

Risk Managers – Discover the key Industry, Political, Economic and Operational risks facing companies in these rapidly developing states, and exploit BMI's quantitatively-based risk assessment model to stress-test your own assumptions.

Country Managers - Gain an insight into the country-specific growth trajectories and the key strengths of your clients and competitors.

Financial Planners – Critically evaluate the assumptions underpinning your medium-term financial projections using BMI's growth projections for the future direction and value of the currency and key domestic interest rates; the principal determinant of business investment and consumer spending growth.

List of over 50 leading OTC companies profiled in Asia Pacific's Leading OTC Medicine Markets:

Australia (Novartis, Roche, Sigma Pharmaceuticals, Herron Pharmaceuticals)

China (GlaxoSmithKline, Merck & Co, Bayer, Hubei Biocause Heilen Pharmaceutical, Shijiazhuang Pharmaceutical)

Hong Kong (Visa Laboratories, GlaxoSmithKline)

India (Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis)

Indonesia (Novartis, GlaxoSmithKline, Bayer, PT Kalbe Farma)

Japan Novartis, GlaxoSmithKline, Eisai)

Malaysia (GlaxoSmithKline, Novartis, Bumimedic, Chemical Company of Malaysia, Kotra Pharma, YSP Southeast Holding)

Pakistan (Novartis, Wyeth)

Philippines (GlaxoSmithKline, Pfizer, Novartis, Bristol-Myers Squibb, Wyeth, Unilab, Pascual Laboratories)

Singapore (GlaxoSmithKline, Haw Par Corporation Ltd)

South Korea (Dong-A, Yuhan Corporation, Daewoong Pharmaceutical, Bukwang Pharmaceutical Company)

Taiwan (GlaxoSmithKline, Novartis)

Thailand (Pfizer, GlaxoSmithKline, Novartis, Government Pharmaceuticals Organisation)

Vietnam (Vietnam OPV Pharmaceutical Co)

正文目录:

Asia Pacific’s OTC Market......................................................................................... 6
chart: Great Variety................................................................................................................................................................... 6
Value Of Asia Pacific’s Major OTC Markets (US$bn)
chart: Dominated By China And India................................................................................................................................... 6
Population Of Asia Pacific’s Major OTC Markets (mn)
chart: Rich And POOR................................................................................................................................................................. 7
Per Capita Sepnding On OTCs In Asia Pacific During 2008 (US$)
chart: aLMOST uNIVERSAL gRO WTH......................................................................................................................................... 7
Percentage Growth Rate Of Asia Pacific’s Major OTC Market (2007 Versus 2008)
table: asia pacific’s major otc markets (Us$bn).................................................................................................... 8
Period 2004-2012, china, australia, indonesia, malaysia, singapore, vietnam, india, pakistan,
japan, south korea, philippines, hong kong, taiwan, thailand
Business Environment Ratings................................................................................. 9
Pharmaceutical Ratings - Methodology..................................................................................9
Ratings System........................................................................................................................9
table: pharmaceutical business environment indicators................................................................................. 9
limits to potential returns, market structure: market expenditure (us$bn), market
expenditure per capita (us$), sector value growth (% y-o-y), country structure, urban-rural
split, pensionable population (% of total), population growth (2003-2015), risks to potential
returns, market risks: intellectual property (ip) laws, policy/reimbursements, approvals
process, country risk: economic structure, policy continuity, bureaucracy, legal framework,
corruption
Indicators.............................................................................................................................10
table: weighting of components.............................................................................................................................. 10
limits of potential returns, –pharmaceutical market, –country structure,
risks to realisation of potential returns, –market risks, –country risk
table: asia pacific business environment rankings........................................................................................... 10
japan, south korea, australia, singapore, china, hong kong, taiwan, india, malaysia,
philippines, thailand, indonesia, vietnam, pakistan
Weighting.............................................................................................................................10
Australia...............................................................................................................................10
China....................................................................................................................................11
Hong Kong...........................................................................................................................11
India.....................................................................................................................................12
Indonesia .............................................................................................................................12
Japan....................................................................................................................................13
Malyasia ...............................................................................................................................14
Pakistan...............................................................................................................................15
Philippines............................................................................................................................15
Singapore.............................................................................................................................16
South Korea..........................................................................................................................16
Taiwan..................................................................................................................................17
Thailand...............................................................................................................................17
Vietnam................................................................................................................................18
Business Monitor International Ltd
Industry Forecast OTC - Q1 2008........................................................................... 20
Australia...............................................................................................................................20
table: australia – otc market forecast indicators........................................................................................... 20
period 2005-2012, otc market (us$bn), otc market (audbn), otc market (as % total market),
analgesic drugs sales, cough and cold drugs sales, digestives, skin treatments, vitamins
and minerals sales
China....................................................................................................................................20
table: china – forecast indicators.......................................................................................................................... 21
period 2005-2012, otc market (us$bn), otc market (cnybn), otc market (as % total market),
analgesic drugs sales (us$mn), cough & cold drugs sales (us$mn), digestives (us$mn), skin
treatments (us$mn), vitamins and minerals sales (us$mn)
Indonesia.............................................................................................................................21
table: indonesia – otc market forecasts............................................................................................................... 22
period 2006-2012, otc market, otc market (idrbn), otc market (as % of total market),
analgesics, cough and cold drugs, digestives, skin treatments, vitamins and minerals
Malaysia...............................................................................................................................22
table: malaysia – otc market forecast indicators............................................................................................. 22
period 2006-2012, otc market (us$bn), otc market (myrbn), otc market (as % total market),
analgesics, cough & cold drugs, digestives, skin treatments, vitamins and minerals
Singapore.............................................................................................................................23
table: singapore – otc market forecast indicators.......................................................................................... 23
period 2006-2012, otc market, otc market (sgdbn), otc market (as % total market),
analgesics, cough and cold drugs, digestives, skin treatments, vitamins and minerals
Vietnam................................................................................................................................24
table: vietnam – otc market data forecasts......................................................................................................... 24
period 2006-2012, otc market, otc market (vndbn), otc market (as % total market),
analgesics, cough and cold, digestives, skin treatments, vitamins and minerals sales
India.....................................................................................................................................24
table: india – otc market forecasts....................................................................................................................... 25
period 2006-2012, otc market (us$bn), otc market (inrbn), otc market (as % total market),
analgesic drugs sales, cough and cold drugs sales, digestives, skin treatments, vitamins
and minerals sales
Pakistan...............................................................................................................................25
table: pakistan – otc drugs market forecasts.................................................................................................... 26
period 2006-2012, otc market, otc market (pkrbn), otc market (as % total market),
analgesics, cough and cold drugs, digestives, skin treatments, vitamins and minerals sales
Japan....................................................................................................................................26
table: japan – otc market indicators...................................................................................................................... 27
period 2005-2012, otc market (us$bn), otc market (jpybn), otc market (as % total market),
analgesic drugs sales, cough and cold drugs sales, digestives, skin treatments, vitamins
and minerals sales
South Korea..........................................................................................................................27
table: south korea – otc market indicators......................................................................................................... 28
period 2006-2012, otc market (us$bn), otc market (krwbn), otc market (as % total market),
analgesics, cough and cold drugs, digestives, skin treatments, vitamins and minerals
Philippines............................................................................................................................28
table: philippines – otc drugs market indicators.............................................................................................. 28
period 2006-2012, otc market (us$bn), otc market (phpbn), otc market (as % total market),
analgesics, cough and cold drugs, digestives, skin treatments, vitamins and minerals
Hong Kong...........................................................................................................................29
table: hong kong – otc market forecast indicators......................................................................................... 29
period 2006-2012, otc market, otc market (hkdbn), otc market (as % total market), analgesics,
cough and cold drugs, digestives, skin treatments, vitamins and minerals (us$mn)
Taiwan..................................................................................................................................30
table: taiwan – otc market forecast indicators................................................................................................. 30
period 2006-2012, otc market (us$bn), otc market (twdbn), otc market (as % total market),
analgesics, cough and cold drugs, digestives, skin treatments, vitamins and minerals
Business Monitor International Ltd
Asia pacific’s leading OTC Medicine Markets
Thailand...............................................................................................................................30
table: thailand – otc drugs market indicators................................................................................................... 31
period 2006-2012, otc market (us$bn), otc market (thbbn), otc market (as % total market),
analgesic drugs, cough and cold drugs, digestives, skin treatments, vitamins and minerals
Company Profiles - Australia................................................................................. 32
Novartis................................................................................................................................32
Roche....................................................................................................................................33
Sigma Pharmaceuticals.........................................................................................................34
Herron Pharmaceuticals.......................................................................................................35
Company Profiles - China....................................................................................... 36
GlaxoSmithKline...................................................................................................................36
Merck & Co............................................................................................................................37
Bayer....................................................................................................................................38
Hubei Biocause Heilen Pharmaceutical................................................................................39
Shijiazhuang Pharmaceutical (CSPC)....................................................................................40
Company Profiles - Indonesia................................................................................ 41
Novartis................................................................................................................................41
GlaxoSmithKline...................................................................................................................42
Bayer....................................................................................................................................43
PT Kalbe Farma.....................................................................................................................44
Company Profiles - Malaysia................................................................................. 47
GlaxoSmithKline (GSK).........................................................................................................47
Novartis................................................................................................................................48
Bumimedic............................................................................................................................49
Chemical Company of Malaysia (CCM)..................................................................................50
Kotra Pharma........................................................................................................................51
YSP Southeast Holding..........................................................................................................52
Company Profiles - Singapore............................................................................... 53
GlaxoSmithKline...................................................................................................................53
Sanofi-Aventis.......................................................................................................................54
Haw Par Corporation Ltd......................................................................................................55
Company Profiles - Vietnam.................................................................................. 56
Vietnam OPV Pharmaceutical Co..........................................................................................56
Company Profiles - India....................................................................................... 57
Pfizer....................................................................................................................................57
GlaxoSmithKline(GSK)..........................................................................................................59
Novartis................................................................................................................................60
Sanofi-Aventis.......................................................................................................................61
Company Profiles - Pakistan.................................................................................. 62
Novartis................................................................................................................................62
Wyeth....................................................................................................................................63
Business Monitor International Ltd
Company Profiles - Japan...................................................................................... 64
Novartis................................................................................................................................64
GlaxoSmithKline (GSK).........................................................................................................66
Eisai......................................................................................................................................68
Company Profiles - South Korea............................................................................ 70
Dong-A.................................................................................................................................70
Yuhan Corporation................................................................................................................72
Daewoong Pharmaceutical...................................................................................................73
Bukwang Pharmaceutical Company.....................................................................................75
Company Profiles - Philippines.............................................................................. 76
GlaxoSmithKline...................................................................................................................76
Pfizer....................................................................................................................................78
Novartis................................................................................................................................79
Bristol-Myers Squibb.............................................................................................................80
Wyeth....................................................................................................................................81
Unilab...................................................................................................................................82
Pascual Laboratories.............................................................................................................84
Company Profiles - Hong Kong.............................................................................. 85
Vida Laboratories.................................................................................................................85
GlaxoSmithKline...................................................................................................................86
Company Profiles - Taiwan.................................................................................... 87
GlaxoSmithKline...................................................................................................................87
Novartis................................................................................................................................88
Company Profiles - Thailand.................................................................................. 89
Pfizer....................................................................................................................................89
GlaxoSmithKline...................................................................................................................90
Novartis................................................................................................................................91
Government Pharmaceutical Organisation (GPO)...............................................................92

如果这份报告还不能满足您的需求,或者您对这份报告还有什么意见或者建议,请您填写以下反馈信息。
百度主题推广
关于我们 | 报告购买帮助 | 定制服务 | 关于佐思软件 | 会员服务申请 | 常见问题 | 版权申明 | 友情链接 | 联系我们
2005-2007 OKOKOK.com.cn All rights reserved. 佐思信息 版权所有 京ICP证041200号
北京:010-51266615 010-82863480/1/2/5 传真:010-82863486 上海:021-64871266 021-64872612 传真:021-64872324
Email: 地址:北京市海淀区五道口华清商务会馆906D(100083)


PDF阅读软件